In 2017, results from phase III trials demonstrated the impressive safety and efficacy of adjuvant targeted and immune therapies in patients with resectable stage III–IV melanoma, and raised questions about the surgical management of patients with microscopic sentinel-lymph-node metastases. For patients with unresectable disease, new overall survival data added to the debate about the relative benefits of single-agent anti-PD-1 versus combined anti-PD-1 and anti-CTLA-4 immunotherapy.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Identification of immune-related biomarkers associated with tumorigenesis and prognosis in cutaneous melanoma patients
Cancer Cell International Open Access 25 May 2020
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Luke, J. J. et al. Targeted agents and immunotherapies: optimizing outcomes in melanoma. Nat. Rev. Clin. Oncol. 14, 463–482 (2017).
Eggermont, A. M. et al. Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial. Lancet Oncol. 16, 522–530 (2015).
Eggermont, A. M. et al. Prolonged survival in stage III melanoma with ipilimumab adjuvant therapy. N. Engl. J. Med. 375, 1845–1855 (2016).
Weber, J. et al. Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma. N. Engl. J. Med. 377, 1824–1835 (2017).
Long, G. V. et al. Adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma. N. Engl. J. Med. 377, 1813–1823 (2017).
Gershenwald, J. E. et al. Melanoma staging: evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J. Clin. 67, 472–492 (2017).
Faries, M. B. et al. Completion dissection or observation for sentinel-node metastasis in melanoma. N. Engl. J. Med. 376, 2211–2222 (2017).
Larkin, J. et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N. Engl. J. Med. 373, 23–34 (2015).
Wolchok, J. D. et al. Overall survival with combined nivolumab and ipilimumab in advanced melanoma. N. Engl. J. Med. 377, 1345–1356 (2017).
Long, G. V. et al. Outcomes in patients (pts) treated with ipilimumab (ipi) after pembrolizumab (pembro) in KEYNOTE-006 [abstract]. Pigm. Cell Melanoma Res. 30, 76–156 (2017).
Acknowledgements
M.A.D. acknowledges funding support from the US National Cancer Institute (grants 1R01CA187076-02, 1U54CA224070-01, and 2T32CA009666-21), The Cancer Prevention and Research Institute of Texas (RP160183), the Melanoma Research Alliance, and the Melanoma Research Foundation. Both M.A.D and K.T.F. acknowledge funding support from the Dr Miriam and Sheldon G. Adelson Medical Research Foundation.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
M.A.D. has served on advisory boards for BMS, Novartis, Roche/Genentech, Sanofi-Aventis, and Vaccinex, and has been the Principal Investigator of studies funded by grants to his institution from AstraZeneca, BMS, Oncothyreon, Roche/Genentech, and Sanofi-Aventis. K.T.F. has served on advisory boards for BMS, Merck, Novartis, and Roche/Genentech, and has received grant support from Novartis.
PowerPoint slides
Rights and permissions
About this article
Cite this article
Davies, M., Flaherty, K. Moving treatments earlier to move further forwards. Nat Rev Clin Oncol 15, 75–76 (2018). https://doi.org/10.1038/nrclinonc.2017.183
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrclinonc.2017.183
This article is cited by
-
Identification of immune-related biomarkers associated with tumorigenesis and prognosis in cutaneous melanoma patients
Cancer Cell International (2020)